Kisspeptin-10 (a fragment of the natural hormone kisspeptin, also called metastin) activates the KISS1R receptor on hypothalamic neurons, triggering GnRH release that in turn drives LH and FSH secretion. Unlike most compounds in this catalog, it has a meaningful body of human clinical research behind it, largely in fertility and reproductive-hormone contexts.
Kisspeptin-10 is a fragment of the kisspeptin peptide, a key upstream regulator of the reproductive hormone axis (it stimulates GnRH release, which drives LH/FSH and downstream sex hormone production). It has real, well-controlled human trial data.
Human trial (bolus dosing, n=6; infusion dosing, n=4, men): a 1μg/kg bolus produced a rapid, dose-dependent LH rise (4.1 to 12.4 IU/L at 30 minutes). A 22.5-hour continuous infusion at 4μg/kg/h raised testosterone from 16.6 to 24.0 nmol/L (P<0.001) and LH from 5.4 to 20.8 IU/L. A lower infusion dose (1.5μg/kg/h) still increased LH pulse frequency significantly (0.7 to 1.0 pulses/hour, P<0.05). George et al., J Clin Endocrinol Metab, 2011
Sex-specific effects: a separate study found kisspeptin-10's effects on reproductive hormone release show sexual dimorphism — the response differs between men and women, worth accounting for rather than treating as a one-size-effect compound.
Human trial doses: 1μg/kg as an acute bolus (LH response), or continuous infusion at 1.5-4μg/kg/hour (sustained LH/testosterone effect) — real clinical research doses, though delivered via controlled infusion in a research setting, not necessarily reflecting typical self-administered dosing patterns.
Not detailed with specific figures in the sources reviewed in this pass — worth a dedicated follow-up look at the full trial's adverse-event reporting before publishing a specific safety claim.
Reproductive hormone signaling, triggering the GnRH-LH-FSH cascade, studied in contexts including fertility restoration, IVF triggering protocols, and sexual desire research.
Yes, more than most research peptides. Multiple human clinical trials have examined it for reproductive hormone stimulation and IVF triggering, giving it a meaningfully larger human evidence base than compounds like BPC-157.
No, it remains an investigational compound, not approved by the FDA for therapeutic use, and is sold for research use only.
Yes — researched as a trigger for ovulation during IVF, with early trials suggesting it might lower the risk of ovarian hyperstimulation syndrome versus standard triggers, though still active research rather than settled practice.
Looking for something specific, or placing a wholesale order? Send us a DM or email.